Holen Sie sich die Stockscreener-App
5.27
1.31%
-0.07
Handel nachbörslich:
5.25
-0.02
-0.38%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts - ts2.tech
Altimmune Amends Loan Agreement with Hercules Capital - MSN
Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect? - Yahoo Finance
Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineALT - ACCESS Newswire
Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025 - ts2.tech
Altimmune Inc (HAM:3G0) Competitors 2025 - GuruFocus
Altimmune (HAM:3G0) ROA % : -36.91% (As of Sep. 2025) - GuruFocus
Altimmune (HAM:3G0) EV-to-EBIT : -4.00 (As of Dec. 08, 2025) - GuruFocus
Altimmune Inc (HAM:3G0) Stock Price, Trades & News - GuruFocus
Geode Capital Management LLC Raises Holdings in Altimmune, Inc. $ALT - MarketBeat
Altimmune: 48-Week MASH Data Due This Month Is Make Or Break For The Company (NASDAQ:ALT) - Seeking Alpha
EBITDA per share of Altimmune, Inc. – LSE:0A4C - TradingView
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down - geneonline.com
Altimmune (ALT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Durso succeeding Garg as Altimmune CEO - BioCentury
Altimmune releases additional phase 2 pemvidutide data for MASH - MSN
Altimmune (NASDAQ:ALT) Stock Price Down 6.6%Time to Sell? - MarketBeat
Investors SueWallSt as Altimmune, Inc. Faces Securities Fraud Allegations - The National Law Review
ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - Stock Titan
Altimmune Announces CEO Transition and Succession Plan - The Globe and Mail
Key facts: Altimmune appoints Jerry Durso as CEO; pemvidutide trial data pending - TradingView
Altimmune announces CEO transition - MSN
Gaithersburg drug developer Altimmune names new CEO as current chief readies exit - The Business Journals
Altimmune stock falls after CEO Garg announces 2026 departure By Investing.com - Investing.com Canada
Altimmune stock falls after CEO Garg announces 2026 departure - Investing.com
Altimmune, Inc. Announces CEO Changes - marketscreener.com
Altimmune CEO Vipin Garg to Step Down - marketscreener.com
Altimmune names Jerry Durso as new CEO effective January 2026 By Investing.com - Investing.com Canada
Altimmune, Inc. Announces CEO Transition - TradingView
Altimmune names Jerry Durso as new CEO effective January 2026 - Investing.com
Altimmune (ALT) Announces CEO Transition Plan - GuruFocus
Altimmune falls as CEO Vipin Garg to step down - TradingView
Altimmune announces leadership change as CEO Vipin Garg steps down - Traders Union
Altimmune, Inc. Announces CEO Transition as Jerry Durso Succeeds Vipin Garg, Ph.D. - Quiver Quantitative
Altimmune announces CEO transition, succession plan - marketscreener.com
Altimmune Announces CEO Transition, Succession Plan - TradingView
Altimmune (Nasdaq: ALT) details CEO handover and late-stage pemvidutide path in MASH - Stock Titan
Intech Investment Management LLC Purchases 73,482 Shares of Altimmune, Inc. $ALT - MarketBeat
Altimmune Investors Drop Suit Over Liver Drug Trial, Stock Drop - Bloomberg Law News
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Altimmune (Nasdaq: ALT) to Present Chat at Piper Sandler 37th Healthcare Conference - Stock Titan
Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know - MSN
ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment - ts2.tech
Altimmune’s RECLAIM STUDY: A New Hope for Alcohol Use Disorder Treatment - MSN
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment - MSN
Net debt of Altimmune, Inc. – HAM:3G0 - TradingView
Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment - MSN
Will Altimmune Inc. stock outperform international peersJuly 2025 Rallies & Low Drawdown Momentum Ideas - newser.com
While institutions invested in Altimmune, Inc. (NASDAQ:ALT) benefited from last week's 10% gain, individual investors stood to gain the most - simplywall.st
How Altimmune Inc. stock benefits from global expansion2025 Big Picture & Verified Entry Point Signals - newser.com
How strong is Altimmune Inc. stock revenue growthWeekly Trend Report & Accurate Intraday Trading Signals - newser.com
Transcript : Altimmune, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-20-2025 08 - MarketScreener
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):